Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector; Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap

修飾

Abhinit Nagar,Jonathan A. Hartonibutors in the Japanese pharmaceutical sector. This chapter outlines the laws and regulations that shape how pharmaceutical markets operate in Japan and describes how these relevant rules interact. It also explores the major challenges the Japanese pharmaceutical industry faces.

indignant

Natasha S. Barteneva,Ivan A. Vorobjevompetition policy. It then reviews the challenges the system faces. The chapter concludes by discussing the issues to be considered further when creating a sustainable healthcare delivery system and enacting competition policies.

Blood-Vessels

Natasha S. Barteneva,Ivan A. Vorobjev held liable arises. A remedial system for health damage caused by the proper use of medicinal products also exists. Although remedies are not limited to damage caused by unknown side effects, a certain set of requirements, different from that for civil liability, must be met to for the plaintiff to

注意力集中

Abhinit Nagar,Jonathan A. Hartony in a cease-and-desist order. The detailed rules set out in the Fair Competition Code are rarely enforced by the industry’s self-regulatory body, which issues only a warning and guidance to violators. Disclosure, rather than prohibition, has become the primary way to control pharmaceutical companie

Debate

https://doi.org/10.1007/978-1-4899-1552-8 Insurance Price List, which determines not only the cost, but also the medicines that can be used for treatment under the universal health insurance system. The MHLW also issues administrative guidance. As such, the pharmaceutical sector is heavily regulated. Despite such regulations, intense compe

壯觀的游行

四指套

去掉

有權(quán)

Book 2022k also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in

嚴(yán)厲批評

2524-504X eutical sector, including competition, intellectual property.This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including econo